Skip to Content

Notice

MK Laboratories, Inc., et al.; Withdrawal of Approval of 3 Abbreviated New Drug Applications for Propoxyphene Products

Document Details

Information about this document as published in the Federal Register.

Enhanced Content

Relevant information about this document from Regulations.gov provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA) is withdrawing approval of three abbreviated new drug applications (ANDAs) for products containing propoxyphene. The basis for the withdrawals is that the products are no longer shown to be safe because propoxyphene puts patients at risk of potentially serious and even fatal heart rhythm abnormalities. The holders of these ANDAs have waived their opportunity for a hearing.

DATES:

Effective September 12, 2014.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

David Joy, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave. Bldg. 51, Rm. 6254, Silver Spring, MD 20993-0002, 301-796-3601.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

On November 18, 2010, after receiving clinical data and other information showing that propoxyphene puts patients at risk of potentially serious and even fatal heart rhythm abnormalities, FDA asked manufacturers of then marketed branded and generic propoxyphene drug products to voluntarily withdraw the products from the U.S. market. In a notice published in the Federal Register of March 10, 2014 (79 FR 13308), FDA withdrew approval of 8 new drug applications (NDAs) and 46 ANDAs for propoxyphene drug products from multiple sources whose application holders agreed in writing to waive their opportunity for a hearing and permit FDA to withdraw approval of the applications. In a separate notice published in the Federal Register of March 10, 2014 (79 FR 13310), FDA's Center for Drug Evaluation and Research (CDER) notified the holders of 3 other approved ANDAs for propoxyphene drug products of their opportunity to request a hearing on CDER's proposal to issue an order, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 355(e)), withdrawing approval of 3 ANDAs for propoxyphene drug products. The following products, all of which FDA Start Printed Page 54730believes were discontinued prior to November 2010, were listed in the notice.

Table 1—Propoxyphene Drug Product Applications for Which FDA Proposed To Withdraw Approval

Application No.DrugApplicant or holder
ANDA 083544Kesso-Gesic (propoxyphene hydrochloride (HCl)) Capsules, 65 milligrams (mg)MK Laboratories Inc., 424 Grasmere Ave., Fairfield, CT 06430.
ANDA 084551Propoxyphene HCl Capsules, 65 mgWhiteworth Towne Paulsen Inc.
ANDA 084553Compound 65 (aspirin, caffeine, and propoxyphene HCl) Capsules, 389 mg/32.4 mg/65 mgAlra Labs, 3850 Clearview Ct., Gurnee, IL 60031.

In its March 10, 2014, notice of opportunity for a hearing, CDER provided these ANDA holders an opportunity to request a hearing to show why approval of the ANDAs should not be withdrawn. No timely request for a hearing on this matter was received following publication of the notice in the Federal Register.

Therefore, under section 505(e) of the FD&C Act and under authority delegated to the Director of CDER by the Commissioner of Food and Drugs, approval of the applications listed in table 1 and all amendments and supplements thereto is withdrawn (see DATES). Introduction or delivery for introduction of these products into interstate commerce without an approved application is illegal and subject to regulatory action (see sections 505(a) and 301(d) of the FD&C Act (21 U.S.C. 331(d))).

Start Signature

Dated: September 5, 2014.

Leslie Kux,

Assistant Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 2014-21729 Filed 9-11-14; 8:45 am]

BILLING CODE 4164-01-P